儿童和青少年慢性髓性白血病一线伊马替尼治疗:一项III期试验结果
一项前瞻性III期试验纳入156例新诊断慢性髓性白血病(CML)儿童和青少年,一线接受伊马替尼治疗,剂量分别为300、400、500 mg/m2。148例可评估患者中,慢性期患者18个月无事件生存率为97%(95% CI, 94.2-99.9%),3个月完全血液学缓解率98%,12个月完全细胞遗传学缓解率63%,18个月主要分子学缓解率59%。
要点
- 慢性期CML患者18个月无事件生存率为97%(95% CI, 94.2-99.9%)。
- 按2006 ELN标准,3个月完全血液学缓解率98%,12个月完全细胞遗传学缓解率63%,18个月主要分子学缓解率59%。
- 38例(27%)因疗效不满意或不耐受(9例)出现伊马替尼治疗失败。
核心结论
- 这项大型儿童试验扩展并证实了较小系列的数据,即儿童一线伊马替尼治疗高度有效。
研究设计与样本
- 前瞻性III期试验,共156例新诊断CML患者(年龄范围1.3-18.0岁,中位13.2岁;91例(58.3%)男性),其中慢性期146例、加速期3例、急变期7例,一线接受伊马替尼治疗(剂量分别为300、400、500 mg/m2),对148例数据完整的儿童和青少年分析治疗反应、无进展生存、治疗失败原因及副作用。
主要发现
- 慢性期患者18个月无事件生存率为97%(95% CI, 94.2-99.9%),中位随访时间25个月(范围1-120)。
- 按2006 ELN标准,3个月完全血液学缓解率98%,12个月完全细胞遗传学缓解率63%,18个月主要分子学缓解率59%。
- 36个月时,86%的患者达到完全细胞遗传学缓解,74%达到主要分子学缓解。
- 38例(27%)因疗效不满意或不耐受(9例)出现伊马替尼治疗失败。
- 148例患者中28例(19%)接受干细胞移植;移植亚组中,慢性期23例中2例、加速期1例中0例、急变期4例中2例分别死于复发(3例)或移植相关并发症(2例)。
关键数值与推荐
- 2006 ELN标准:3个月完全血液学缓解、12个月完全细胞遗传学缓解、18个月主要分子学缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m2, respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.
引用
- Suttorp M, Schulze P, Glauche I, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018. PMID: 29925908. doi:10.1038/s41375-018-0179-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。